Invesco Nasdaq Biotechnology ETF News

The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in develo

Although biotechnology stocks have been lackluster for the past year, the industry is gaining increased attention of late, not just for the role it's played in combatting the COVID-19 pandemic, but al

Innovative biotechnology companies are coming out with novel treatments in the healthcare industry. Investors can also capture the ongoing innovations in the biotech sector through a targeted exchange

As is now widely documented, biotechnology stocks and exchange traded funds endured a rough 2021. Compounding those woes is the fact that investors were caught off guard by last year's lethargy becaus

The biotechnology industry is often a hotbed of mergers and acquisitions speculation. Announced deals are a different matter altogether.

Moderna (NasdaqGS: MRNA) jumped on Monday after announcing that a higher dosage booster of its vaccine could help mitigate COVID-19 Omicron risks before a tailor-made shot is finalized, lifting biotec

Broadly speaking, 2021 hasn't been kind to biotechnology stocks and exchange traded funds, but some market participants remain optimistic regarding a rebound for these previously beloved assets. One w

While Covid-19 variants on the rise, the push for more vaccinations make the Invesco Nasdaq Biotechnology ETF (IBBQ) an ETF to watch. As Covid cases experience a resurgence, more companies are mandat

As investors consider the regulatory, scientific, and demographic factors driving today's growth in biotechnology industry, they can look to the Nasdaq Biotechnology Index's methodology and one relate

The Nasdaq Biotechnology Index (NBI) launched in 1993, when the industry was still in the midst of the original “biotech revolution.” Since then, its constituent basket has swelled from roughly 10